- Home
- RNA vs ARWR Comparison
RNA vs ARWR Comparison
Compare RNA & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RNA | ARWR |
|---|---|---|
| Founded | 2012 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9B | 10.1B |
| IPO Year | 2020 | 2009 |
Fundamental Metrics
Financial Performance| Metric | RNA | ARWR |
|---|---|---|
| Price | $72.90 | $62.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 20 | 11 |
| Target Price | $69.26 | ★ $77.55 |
| AVG Volume (30 Days) | 2.1M | ★ 2.7M |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 0.69 | ★ 99.80 |
| EPS | N/A | ★ 0.22 |
| Revenue | $10,897,000.00 | ★ $16,142,321.00 |
| Revenue This Year | $88.12 | N/A |
| Revenue Next Year | $18.11 | N/A |
| P/E Ratio | ★ N/A | $289.05 |
| Revenue Growth | ★ 13.99 | N/A |
| 52 Week Low | $25.28 | $10.66 |
| 52 Week High | $73.06 | $76.76 |
Technical Indicators
Market Signals| Indicator | RNA | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 64.95 | 44.14 |
| Support Level | $70.42 | $60.53 |
| Resistance Level | $73.04 | $71.83 |
| Average True Range (ATR) | 0.21 | 3.45 |
| MACD | -0.05 | -0.34 |
| Stochastic Oscillator | 60.24 | 16.17 |
Price Performance
Historical ComparisonAbout RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.